AstraZeneca has announced that the EC has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer whose tumours have exon 19 deletions or exon 21 mutations.

Www.pharmatimes.com/croy

Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction and Embryology (ESHRE) 40th annual meeting, which was held in Amsterdam, the Netherlands.

Pharmarole.com

Welcome to the july/august issue of pharmafocus!

Evaluating the infected blood scandal and the outcomes of its inquiry

Www.samedanltd.com

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia, following its approval in January 2024.

AbbVie has announced that the EMA's CHMP has granted a positive opinion to Tepkinly (epcoritamab), recommending the conditional marketing authorisation of the drug as a monotherapy treatment for adult patients with relapsed or refractory (r/r) follicular lymphoma (fl).

Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand UNICEF's work to ‘improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India’, according to the press release.

The FDA has granted an expanded orphan drug designation (ODD) for brain cancer immunotherapy survaxm, originally created at Roswell Park Comprehensive Cancer Center.

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the twice-yearly treatment with injectable HIV-1 capsid inhibitor, lencapavir, for the investigational use of HIV prevention in cisgender women.

Takeda has announced data from the phase 3 advance-cidp 3 trial, which assessed the safety and efficacy of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with chronic inflammatory dymyelinating polyneuropathy (CIDP).

CPHI Worldwide

Sanofi has announced new phase 2 trial data for its cd40l monoclonal antibody, frexalimab, for the treatment of patients with relapsing multiple sclerosis (MS).

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study, which assessed Primec for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Comms.pharmatimes.com/

Merck has announced that the FDA has approved capvaxive (pneumococcal 21-valent conjugate vaccine).

Eli Lilly has announced that the FDA has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for iv infusion) for the treatment of adult patients with early symptomatic Alzheimer’s disease (AD).

Www.iptonline.com

AbbVie has announced that the FDA has approved Skyrizi (risankizumab-rzaa) for the treatment of adult patients with moderately-to-severely active ulcerative colitis (UC) and moderate to severe crohn’s disease.

Sarepta Therapeutics has announced that the FDA has approved an expansion to the labelled indication for Elevidys (delandistrogene moxapar vovec-rokl) to include individuals with DMD with a confirmed mutation in the DMD gene who are at least four years of age.

GSK and CureVac have announced that they have restructured their existing collaboration into a licence agreement, which is intended to allow both companies to prioritise investment and focus their respective MRNA development programmes.

Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a research payment of $20m to Evotec.

Https://pmeaawardsplatform.com/

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology in-licensed from excellgene alongside syngene’s clone selection and development processes.

Merck and EyeBiotech Limited, have announced that the two companies have entered into a definitive agreement under which Merck, through one of its subsidiaries, will acquire EyeBio.

Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon.

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global compounding operator as well as to allow icon to enter the UK market.

Konrad Werhahn from UCB discusses how disease-modifying solutions may introduce a new era in treatment for epilepsies

Alex Fong and Olivia Houselander from Owen Mumford Pharmaceutical Services consider the action needed to make drug discovery processes more sustainable

Rajul Jain from ProPharma considers how AI can be used in patient support, especially considering how it can be used to streamline operations and supplement human expertise

Www.pharmafocus.com

Betsy Goodfellow from Pharmafocus considers the details of the infected blood scandal, from its beginning to the outcome of the recent inquiry

Www.flypharmaeurope.com

With his 20 years of expertise and proven track record in biotech and pharmaceutical industries, Curve Therapeutics appoints Simon Jones as chief financial officer and chief operating officer.

Vectory Therapeutics has announced the appointment of Adam Rosenberg as chair of the board, replacin Dr Carlo Incerti.

Mogrify has announced the appointment of Dr Jonathan Appleby as chief scientific officer.

Professor Yih-Shing Duh appointed as chief scientific advisor by H.E.L. Group

Read on for five key facts about blood transfusions

Get in touch @pharmafocus